Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia. While ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

The three major histopathological subtypes of RCC are clear cell carcinoma (ccRCC), papillary carcinoma (pRCC), and chromophobe renal cell carcinoma (chrRCC). Studies have reported that ccRCC has the ...